| Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma (NCT05053659) | Paolo Caimi, MD | 2022-06-20 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome (NCT04978779) | Vincerx Pharma, Inc. | 2021-12-16 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NCT05420493) | Chongqing Precision Biotech Co., Ltd | 2021-09-06 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
| Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (NCT03938987) | University of Alberta | 2021-03-03 |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (NCT04150913) | Marcela V. Maus, M.D.,Ph.D. | 2020-10-01 |
| A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma (NCT04539444) | The First Affiliated Hospital of Soochow University | 2020-08-01 |
| Polatuzumab Vedotin in Patients With Relapsed and Refractory Diffuse Large B Cell Lymphoma (NCT05006534) | National Taiwan University Hospital | 2020-06-01 |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (NCT03774654) | Baylor College of Medicine | 2020-04-14 |
| Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04012892) | Chinese PLA General Hospital | 2019-05-01 |
| Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT03719989) | Seoul National University Hospital | 2018-12-01 |
| MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (NCT03778619) | GC Cell Corporation | 2018-11-28 |
| Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma (NCT03505944) | Nordic Lymphoma Group | 2018-07-01 |
| Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma (NCT03540303) | Henan Cancer Hospital | 2018-04-12 |
| Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma (NCT03892421) | La Raza Medical Center | 2018-04-05 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (NCT03091933) | Ciusss de L'Est de l'Île de Montréal | 2017-02-06 |
| Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma (NCT02875067) | NYU Langone Health | 2016-08-29 |
| Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (NCT01811368) | Joseph Tuscano | 2013-03-12 |
| Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL (NCT03042585) | Loyola University | 2006-06-01 |
| Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma (NCT02099292) | Georg Hess, MD | 2001-05-01 |